TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31843833

Group type: EXPERIMENTAL
Intervention: Luteal phase progesterone supplementation from early luteal phase until gestational age 8 weeks
Number of subjects: 604

Group type: COMPARATOR
Intervention: No luteal phase progesterone supplementation
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Blastocyst warming and transfer on day 6 after ovulation trigger
Number of subjects: 604

Group type: COMPARATOR
Intervention: Blastocyst warming and transfer on day 7 after ovulation trigger
Number of subjects: 604
Study: 28387798

Group type: EXPERIMENTAL
Intervention: IVM
Number of subjects: 63

Group type: COMPARATOR
Intervention: IVF
Number of subjects: 63

Group type: COMPARATOR
Intervention: ICSI
Number of subjects: 63

Group type: COMPARATOR
Intervention: Pooled ART (IVM, IVF, ICSI)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Spontaneous conception
Number of subjects: 63
Study: 25739642

Group type: EXPERIMENTAL
Intervention: Yoga and meditation intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study: 23573878

Group type: EXPERIMENTAL
Intervention: Laparoscopic inguinal hernia repair (LIHR)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Lichtenstein tension‐free hernia repair
Number of subjects: 252

Group type: COMPARATOR
Intervention: TAPP repair
Number of subjects: 252

Group type: COMPARATOR
Intervention: TEP repair
Number of subjects: 252
Study: 22010915

Group type: EXPERIMENTAL
Intervention: Earlier-ART group (ART initiated within 4 weeks after the start of tuberculosis treatment, 214 patients)
Number of subjects: 642

Group type: COMPARATOR
Intervention: Later-ART group (ART initiated during the first 4 weeks of the continuation phase of tuberculosis treatment, 215 patients)
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Earlier-ART group
Number of subjects: 642

Group type: COMPARATOR
Intervention: Later-ART group
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Patients with CD4+ T-cell counts of less than 50 per cubic millimeter
Number of subjects: 642
Study: 20151522

Group type: EXPERIMENTAL
Intervention: Single dose of rocuronium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cumulative fractional doses of rocuronium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bolus dose of 400 microg-Kg(‐1) of rocuronium
Number of subjects: 0
Study: 16675783

Group type: EXPERIMENTAL
Intervention: Urokinase
Number of subjects: 60

Group type: COMPARATOR
Intervention: VATS
Number of subjects: 60
Study: 12855209

Group type: EXPERIMENTAL
Intervention: Cancer screening module (intervention)
Number of subjects: 530

Group type: COMPARATOR
Intervention: Physical activity module (control)
Number of subjects: 530
Study: 10863856

Group type: EXPERIMENTAL
Intervention: Ribavirin 1,200 mg/day for 24 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 9197874

Group type: EXPERIMENTAL
Intervention: Hormonal Replacement Therapy (HRT)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Continuous combined HRT
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Sequential HRT
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo/untreated
Number of subjects: 73
Study: 1332094

Group type: EXPERIMENTAL
Intervention: MCPP (0.35 mg/kg)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 3547757

Group type: EXPERIMENTAL
Intervention: Budesonide (1600 micrograms/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (1500 micrograms/day)
Number of subjects: 28
Study: 31609137

Group type: EXPERIMENTAL
Intervention: Chewing sugarless gum every 2 hours for 15 minutes starting at the second postoperative hour
Number of subjects: 109

Group type: COMPARATOR
Intervention: Standard postoperative care (Control group)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Chewing sugarless gum
Number of subjects: 109
Study: 31022328

Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 6190

Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 6190
Study: 26797808

Group type: EXPERIMENTAL
Intervention: New pharmacokinetic model for hydromorphone during TCI-PCA
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional patient controlled analgesia (PCA)
Number of subjects: 50
Study: 26409014

Group type: EXPERIMENTAL
Intervention: Etonogestrel (ENG) implant
Number of subjects: 2982

Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG) implant
Number of subjects: 2982

Group type: COMPARATOR
Intervention: Copper IUD (TCu380A)
Number of subjects: 2982
Study: 24119351

Group type: EXPERIMENTAL
Intervention: 1-day live, expert-led educational session
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Self-paced DVD with similar content
Number of subjects: 403

Group type: COMPARATOR
Intervention: Control group (delayed intervention)
Number of subjects: 403
Study: 22208901

Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (subsequent use after etomidate)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control (no etomidate)
Number of subjects: 62
Study: 18082737

Group type: EXPERIMENTAL
Intervention: Metformin tablets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate tablets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metformin dosing compliance
Number of subjects: 0
Study: 15843631

Group type: EXPERIMENTAL
Intervention: Single pulse transcranial magnetic stimulation (TMS) to the right frontal eye field (FEF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single pulse transcranial magnetic stimulation (TMS) to a right posterior control site
Number of subjects: 0
Study: 12921333

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 160
Study: 11406744

Group type: EXPERIMENTAL
Intervention: Serious adverse drug reactions observed by general practitioners
Number of subjects: 254
Study: 9003851

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) at a dosage of 15 mg/kg per day, increased to 30 mg/kg per day if necessary
Number of subjects: 19
Study: 8216015

Group type: EXPERIMENTAL
Intervention: 0.006% PhXA41
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 3315586

Group type: EXPERIMENTAL
Intervention: Anisoylated plasminogen streptokinase activator complex (APSAC) 30U
Number of subjects: 10

Group type: COMPARATOR
Intervention: Streptokinase 1,500,000U
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: APSAC
Number of subjects: 10

Group type: COMPARATOR
Intervention: Streptokinase
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: APSAC and Streptokinase
Number of subjects: 10
Study: 29248433

Group type: EXPERIMENTAL
Intervention: Digital self-guided breathing retraining intervention (DVD plus printed booklet)
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Face-to-face breathing retraining sessions
Number of subjects: 655

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: All groups (DVDB, face-to-face, and usual care)
Number of subjects: 655
Study: 26940689

Group type: EXPERIMENTAL
Intervention: oral morphine
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: oxycodone
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: transdermal fentanyl
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: buprenorphine
Number of subjects: 520
Study: 24712653

Group type: EXPERIMENTAL
Intervention: 1.2 g of a standardized ginger extract per day (300 mg per capsule, administered q.i.d for five days during the first three cycles of chemotherapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard anti-emetic therapy (placebo)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.2 g of a standardized ginger extract per day
Number of subjects: 0
Study: 22574741

Group type: EXPERIMENTAL
Intervention: 300 ml apple juice
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 600 ml apple juice
Number of subjects: 12

Group type: COMPARATOR
Intervention: 50 mg atenolol with 300 ml water
Number of subjects: 12
Study: 21282869

Group type: EXPERIMENTAL
Intervention: TENS with exercise
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo and exercise
Number of subjects: 36

Group type: COMPARATOR
Intervention: Exercise only
Number of subjects: 36
Study: 18794187

Group type: EXPERIMENTAL
Intervention: Internet‐based cognitive‐behavioral therapy (NET)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Wait-list (WL)
Number of subjects: 73
Study: 16536195

Group type: EXPERIMENTAL
Intervention: Adper Scotchbond Multi‐Purpose
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: iBond
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Nano-Bond
Number of subjects: 96

Group type: COMPARATOR
Intervention: All adhesive systems
Number of subjects: 96
Study: 14580052

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 44

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 44
Study: 10827384

Group type: EXPERIMENTAL
Intervention: New York State multivariate risk score
Number of subjects: 3387

Group type: EXPERIMENTAL
Intervention: High-risk lesion characteristics (calcium, thrombus, type C lesion)
Number of subjects: 3387
Study: 9313245

Group type: EXPERIMENTAL
Intervention: Somnium (lorazepam 1 mg plus diphenhydramine 25 mg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Lorazepam (1 mg)
Number of subjects: 44
Study: 8365305

Group type: EXPERIMENTAL
Intervention: ATIII (90 to 120 IU/kg in loading dose, then 90 to 120 IU/kg/d during 4 days)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: ATIII
Number of subjects: 35
Study: 3501753

Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy (EST)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 300
Study: 29780153

Group type: EXPERIMENTAL
Intervention: Infliximab (IFX) treatment
Number of subjects: 301

Group type: COMPARATOR
Intervention: Food-specific IgGs against egg, milk, wheat, corn, rice, tomato, codfish, and soybean
Number of subjects: 301

Group type: COMPARATOR
Intervention: Total serum IgG and IgE levels
Number of subjects: 301

Group type: COMPARATOR
Intervention: Corn- and tomato-specific IgGs
Number of subjects: 301

Group type: COMPARATOR
Intervention: Egg-, milk-, and wheat-specific IgGs
Number of subjects: 301
Study: 27429039

Group type: EXPERIMENTAL
Intervention: Nasojejunal early enteral nutrition (NJEEN)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: NJEEN
Number of subjects: 204

Group type: COMPARATOR
Intervention: TPN
Number of subjects: 204
Study: 24669774

Group type: COMPARATOR
Intervention: Conventional fractionation
Number of subjects: 124

Group type: COMPARATOR
Intervention: Accelerated fractionation
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Maximal interincisal distance
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Dose to the ipsilateral masseter
Number of subjects: 124
Study: 21734980

Group type: EXPERIMENTAL
Intervention: Potassium oxalate‐based desensitizing agent (BisBlock) with Adper Single Bond 2 adhesive
Number of subjects: 40

Group type: COMPARATOR
Intervention: Adper Single Bond 2 adhesive without desensitizing agent
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: One‐Step adhesive with potassium oxalate‐based desensitizing agent (BisBlock)
Number of subjects: 40

Group type: COMPARATOR
Intervention: One‐Step adhesive without desensitizing agent
Number of subjects: 40
Study: 20092585

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Number of subjects: 641

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 641
Study: 18432386

Group type: EXPERIMENTAL
Intervention: Micropolitan areas (medium and large towns)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Metropolitan areas
Number of subjects: 62

Group type: COMPARATOR
Intervention: Noncore areas (rural areas without towns and with small towns)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Metropolitan and micropolitan areas
Number of subjects: 62
Study: 22011421

Group type: EXPERIMENTAL
Intervention: Direct-to-smoker (DTS) outreach offering free tobacco treatment including up to 8 weeks of nicotine patches (NRT)
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: Direct-to-smoker (DTS) outreach offering free tobacco treatment
Number of subjects: 590

Group type: COMPARATOR
Intervention: Usual clinical care
Number of subjects: 590
Study: 16120137

Group type: EXPERIMENTAL
Intervention: Active Behçet's disease (n = 26)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Inactive Behçet's disease (n = 23)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Total Behçet's disease patients (n = 49)
Number of subjects: 49
Study: 11975712

Group type: EXPERIMENTAL
Intervention: Pramlintide 30 microg t.i.d. for 5 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pramlintide 60 microg t.i.d. for 5 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (0 microg pramlintide)
Number of subjects: 12
Study: 9438756

Group type: EXPERIMENTAL
Intervention: Splenectomy
Number of subjects: 55

Group type: COMPARATOR
Intervention: No splenectomy
Number of subjects: 55
Study: 7866397

Group type: EXPERIMENTAL
Intervention: Indigenized group counselling programme
Number of subjects: 100
Study: 2681076

Group type: EXPERIMENTAL
Intervention: 1% hydrocortisone plus 10% urea
Number of subjects: 0

Group type: COMPARATOR
Intervention: hydrocortisone 17-valerate
Number of subjects: 0
Study: 789436

Group type: EXPERIMENTAL
Intervention: Flunisolide (0.025% solution, two sprays in each nostril twice a day for 4 weeks)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Vehicle alone (control group)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Flunisolide
Number of subjects: 51

Group type: COMPARATOR
Intervention: Flunisolide and Vehicle
Number of subjects: 51
Study: 11564390

Group type: EXPERIMENTAL
Intervention: Omapatrilat 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omapatrilat 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omapatrilat 25 mg and 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omapatrilat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30946283

Group type: EXPERIMENTAL
Intervention: Laparoscopic pelvic organ prolapse suspension operation
Number of subjects: 368
Study: 30811620

Group type: EXPERIMENTAL
Intervention: Microwave treatment at maximum energy level (5.8 GHz/axilla)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Microwave treatment
Number of subjects: 26
Study: 29937431

Group type: EXPERIMENTAL
Intervention: Sotagliflozin 200 mg
Number of subjects: 782

Group type: EXPERIMENTAL
Intervention: Sotagliflozin 400 mg
Number of subjects: 782

Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Number of subjects: 782

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 782
Study: 26479510

Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade (NMB) and low-pressure pneumoperitoneum (8 mmHg)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Moderate neuromuscular blockade (single bolus of rocuronium 0.3 mg kg with spontaneous recovery) and standard-pressure pneumoperitoneum (12 mmHg)
Number of subjects: 99
Study: 24679838

Group type: EXPERIMENTAL
Intervention: Dog technique (n = 30)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Toggle-Recoil technique (n = 30)
Number of subjects: 60
Study: 22339943

Group type: EXPERIMENTAL
Intervention: Brief tobacco intervention during dental check-ups (up to four interventions)
Number of subjects: 2586

Group type: COMPARATOR
Intervention: Control group (born on even days)
Number of subjects: 2586
Study: 20456674

Group type: EXPERIMENTAL
Intervention: Postdonation adapted motivational interview (AMI)
Number of subjects: 215

Group type: COMPARATOR
Intervention: No-interview control group
Number of subjects: 215
Study: 17505728

Group type: EXPERIMENTAL
Intervention: Bromopride (5 mg/ml, 2 ml intravenous dose)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride, 2 ml intravenous dose)
Number of subjects: 352
Study: 15741614

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (50 units)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline solution (placebo)
Number of subjects: 40
Study: 12570110

Group type: EXPERIMENTAL
Intervention: Home hospitalisation (HH)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 222
Study: 10337859

Group type: EXPERIMENTAL
Intervention: Mesterolone 100 mg orally daily (MES)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate 160 mg orally daily (TU)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate 250 mg intramuscularly every 21 days (TE)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Single subcutaneous implantation of crystalline testosterone 1,200 mg (TPEL)
Number of subjects: 55
Study: 8620719

Group type: EXPERIMENTAL
Intervention: Nicotine polacrilex (NP) 2 mg
Number of subjects: 3923

Group type: EXPERIMENTAL
Intervention: Nicotine polacrilex (NP)
Number of subjects: 3923

Group type: COMPARATOR
Intervention: Intensive instruction and monitoring of NP use
Number of subjects: 3923
Study: 2015332

Group type: EXPERIMENTAL
Intervention: m-CPP (0.5 mg/kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: m-CPP
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 7202826

Group type: EXPERIMENTAL
Intervention: Indobufen (3 single oral doses)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Indobufen (same dose)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Indobufen (increasing doses)
Number of subjects: 6
Study: 31860533

Group type: EXPERIMENTAL
Intervention: Fast-tempo music (tempo ranging between 137 and 160 b·min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No music
Number of subjects: 10
Study: 31350765

Group type: EXPERIMENTAL
Intervention: 12-week empowerment-based self-care program
Number of subjects: 236

Group type: COMPARATOR
Intervention: Didactic education program
Number of subjects: 236
Study: 30303950

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided cutting-needle pleural biopsy
Number of subjects: 196

Group type: COMPARATOR
Intervention: Thoracoscopic pleural biopsy
Number of subjects: 196
Study: 27265269

Group type: EXPERIMENTAL
Intervention: Flaxseed components
Number of subjects: 0
Study: 25322572

Group type: EXPERIMENTAL
Intervention: Vacuum-sealing drainage (VSD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional pressure dressing and drainage (control group)
Number of subjects: 60
Study: 22040521

Group type: COMPARATOR
Intervention: Ketoconazole (400 mg once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Valproic acid (VPA, sodium valproate, 1000 mg once daily)
Number of subjects: 0
Study: 19410093

Group type: EXPERIMENTAL
Intervention: 15% EDTA
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 10% citric acid
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 10% sodium citrate
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: apple vinegar
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 5% acetic acid
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 5% malic acid
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: sodium hypochlorite
Number of subjects: 42
Study: 17449576

Group type: EXPERIMENTAL
Intervention: Psyllium (7.28 g) and plant sterols (2 g)
Number of subjects: 33
Study: 15915460

Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 12225726

Group type: EXPERIMENTAL
Intervention: BNP measurement using Shionogi and Biosite assays
Number of subjects: 2042

Group type: EXPERIMENTAL
Intervention: BNP measurement for detection of reduced ejection fraction
Number of subjects: 2042
Study: 9798807

Group type: EXPERIMENTAL
Intervention: Omeprazole treatment
Number of subjects: 33

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 33
Study: 7900627

Group type: EXPERIMENTAL
Intervention: Ambulatory 24-hour Holter monitor recordings
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Spectral analysis of heart rate variability (HRV)
Number of subjects: 20
Study: 2719896

Group type: EXPERIMENTAL
Intervention: 30 mg buccal morphine
Number of subjects: 40

Group type: COMPARATOR
Intervention: 10 mg intramuscular morphine
Number of subjects: 40
Study: 835542

Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid 250 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid 500 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid 750 mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (0 mg)
Number of subjects: 13
Study: 31136549

Group type: EXPERIMENTAL
Intervention: Red Spinach Extract (RSE) 1 g daily for 7 days
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 17
Study: 30022620

Group type: EXPERIMENTAL
Intervention: Self-care guide package and three face-to-face educational sessions
Number of subjects: 152

Group type: COMPARATOR
Intervention: Routine clinical services (control)
Number of subjects: 152
Study: 27861932

Group type: EXPERIMENTAL
Intervention: Swallow therapy interventions
Number of subjects: 168
Study: 25885432

Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention (booklet format) with follow-up phone calls for 12 weeks
Number of subjects: 121

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 121
Study: 24195839

Group type: EXPERIMENTAL
Intervention: Verum acupuncture and placebo medicine
Number of subjects: 184

Group type: COMPARATOR
Intervention: Sham acupuncture and Naproxen Sustained Release Tablets
Number of subjects: 184
Study: 21334853

Group type: EXPERIMENTAL
Intervention: Perphenazine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total serum cholesterol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triglycerides
Number of subjects: 0
Study: 19808338

Group type: EXPERIMENTAL
Intervention: PAC
Number of subjects: 133

Group type: COMPARATOR
Intervention: CLIN
Number of subjects: 133
Study: 17567343

Group type: EXPERIMENTAL
Intervention: Cooled saline bag (study group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline bag at room temperature (control group)
Number of subjects: 100